Home › Research › Treatments
Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease
Brant Mittler, Xavier Cambi, Morgan Biskach, Joel Reisman, Ying Wang, Dan Berlowitz, Peter Morin, Donald R Miller et al.. Journal of neurology, 2025-04-16
Topic: Drug trials: efficacy and safety
From an initial sample (N = 2499), 1064 patients (55,000 notes) were reviewed manually (mean age 76 years; 7.3% women; 9.2% Black; 3.9% Hispanic). The AAT group (n = 56) had lower rates of common comorbidities, except post-traumatic stress disorder, than patients excluded from AAT (n = 528). The documented notes including "Lack of patient interest/resource constraints" (24.6% vs 3.6%), "anticoagulant use" (23.1% vs 10.7%), and "advanced AD" (18.6% vs 0), supplied partial explanations on exclusion vs inclusion. Only 5.3% of patients reached the point of care of being a candidate, scheduled for, or receiving AAT infusion. Patient preference and clinician discretion, especially regarding modifiable factors (e.g., medication regimens), appreciably influence the patient journey to AAT.
Key findings
- From an initial sample (N = 2499), 1064 patients (55,000 notes) were reviewed manually (mean age 76 years; 7.3% women; 9.2% Black; 3.9% Hispanic).
- The AAT group (n = 56) had lower rates of common comorbidities, except post-traumatic stress disorder, than patients excluded from AAT (n = 528).
- The documented notes including "Lack of patient interest/resource constraints" (24.6% vs 3.6%), "anticoagulant use" (23.1% vs 10.7%), and "advanced AD" (18.6% vs 0), supplied partial explanations on exclusion vs inclusion.
- Only 5.3% of patients reached the point of care of being a candidate, scheduled for, or receiving AAT infusion.
- Patient preference and clinician discretion, especially regarding modifiable factors (e.g., medication regimens), appreciably influence the patient journey to AAT.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants2,499
- Effect size7.3%; 9.2%; 3.9%
- Evidence strengthLow
How this study scored 57/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 32 of the 56 points we could judge it on, which is 57 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,499 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40237866) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 32 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 32 of the 56 points we could judge it on is 57 out of 100. |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Mittler, B., Cambi, X., Biskach, M., Reisman, J., Wang, Y., Berlowitz, D., et al. (2025). Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease. Journal of neurology. https://doi.org/10.1007/s00415-025-13059-3
Vancouver
Mittler B, Cambi X, Biskach M, Reisman J, Wang Y, Berlowitz D, et al. Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease. Journal of neurology. 2025. doi:10.1007/s00415-025-13059-3. PMID: 40237866.
BibTeX
@article{mittler2025-40237866,
author = {Mittler, Brant and Cambi, Xavier and Biskach, Morgan and Reisman, Joel and Wang, Ying and Berlowitz, Dan and Morin, Peter and Miller, Donald R and others},
title = {{Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease}},
journal = {Journal of neurology},
year = {2025},
doi = {10.1007/s00415-025-13059-3},
pmid = {40237866},
url = {https://doi.org/10.1007/s00415-025-13059-3}
}
Related studies in Treatments
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.